Company intelligence / Profile preview
StemSight
Tampere, Finlandstemsight.fi ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
StemSight develops off-the-shelf regenerative cell therapies using iPSC-derived limbal stem cells and biomaterial scaffolds to treat severe forms of corneal blindness such as LSCD. The company has raised €2.3 million in early funding to advance preclinical studies, expand R&D, pilot manufacturing, and prepare for first-in-human clinical trials. No published human efficacy data yet; preclinical progress reported.
- Therapeutic areas
- Ophthalmology
- Modalities
- Induced pluripotent stem cells (iPSCs)Cell therapyBiomaterials (as delivery/support technology)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Participating in the €8M EU-funded KeratOPrinter Project; no major pharma partnerships disclosed as of May 2025.
Beyond the preview
Go deeper on StemSight.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on StemSight.